bcbs fep glp-1 coverage 2025 Trump plan on weight loss drugs fails Americans Who Gets the Shot? GLP-1

nejm.org/doi/full/10.10 Tirzepatide was the first dual GLP-1 and glucose-dependent insulinotropic peptide receptor agonist approved for the treatment of type 2 diabetes on the basis of the SURPASS-1 (Tirzepatide [LY3298176] in Participants with Type 2 Diabetes Not Controlled with Diet and Exercise Alone) trial, a randomized, placebo-controlled trial of tirzepatide (administered in weekly doses of 5 mg, 10 mg, or 15 mg) paired with metformin for treatment of type 2 diabetes (seen in figure)

Managing the most common side effects Nausea is the most frequently reported side effect, particularly in the first 48 weeks as the dose is being escalated

ACS Pharmacol Transl Sci (2023) 6(5):77182

He worked as a postdoctoral researcher at M.I.T

I have been using this website for 2 years